- Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4. [Journal Article]J Clin Oncol. 2026 Aug 06; :101200JCO2601898. [Online ahead of print]JC
- [Box: see text]Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines fol…
- Publisher Full Text (DOI)
- Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2. [Journal Article]J Clin Oncol. 2026 Aug 06; :JCO2600260. [Online ahead of print]JC
- CONCLUSIONS: Dexrazoxane exerts a significant doxorubicin cardioprotective effect on LV systolic function long term and may reduce screening needs.
- Publisher Full Text (DOI)
- Therapeutic Strategy Concerns for BRAF V600E-Mutated Differentiated Thyroid Cancer. [Letter]J Clin Oncol. 2026 Aug 06; :JCO2601219. [Online ahead of print]JC
- Publisher Full Text (DOI)
- Should Artificial Intelligence Direct Systemic Therapy Decisions in Pancreatic Cancer? [Editorial]J Clin Oncol. 2026 Aug 06; :JCO2600303. [Online ahead of print]JC
- Publisher Full Text (DOI)
- Modernizing Drug Development for Exceptional Therapies in High‑Unmet Need Diseases: A Call for Pragmatism and Patient Centricity. [Journal Article]J Clin Oncol. 2026 Aug 06; :JCO2601367. [Online ahead of print]JC
- Publisher Full Text (DOI)
- Reply to: Therapeutic Strategy Concerns for BRAF V600E-Mutated Differentiated Thyroid Cancer. [Journal Article]J Clin Oncol. 2026 Aug 06; :JCO2601611. [Online ahead of print]JC
- Publisher Full Text (DOI)
- Reply to: "Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration" and "NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002". [Journal Article]J Clin Oncol. 2026 Aug 05; :JCO2601677. [Online ahead of print]JC
- Publisher Full Text (DOI)
- Importance of Inclusion of Representative Populations in Pivotal Clinical Trials: Zolbetuximab as an Example. [Journal Article]J Clin Oncol. 2026 Aug 05; :JCO2601002. [Online ahead of print]JC
- Publisher Full Text (DOI)
- NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002. [Letter]J Clin Oncol. 2026 Aug 05; :JCO2601043. [Online ahead of print]JC
- Publisher Full Text (DOI)
- Innovate or Be Left Behind: A Path to Prospective External Control Arms for Accelerated Oncology Drug Development. [Journal Article]J Clin Oncol. 2026 Aug 05; :JCO2601081. [Online ahead of print]JC
- Publisher Full Text (DOI)
- Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration. [Letter]J Clin Oncol. 2026 Aug 05; :JCO2600911. [Online ahead of print]JC
- Publisher Full Text (DOI)
- Unexpected Lack of Efficacy of Liposomal-Encapsulated Daunorubicin/Cytarabine in Pediatric FLT3 Wild-Type Newly Diagnosed AML. [Editorial]J Clin Oncol. 2026 Aug 05; :JCO2601399. [Online ahead of print]JC
- Publisher Full Text (DOI)
- Chemoimmunotherapy in Deficient DNA Mismatch Repair Metastatic Colorectal Cancer: What COMMIT Can and Cannot Tell Us. [Editorial]J Clin Oncol. 2026 Aug 04; :JCO2601637. [Online ahead of print]JC
- Publisher Full Text (DOI)
- Darolutamide Alone and in Combination With Goserelin in Androgen Receptor-Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial. [Journal Article]J Clin Oncol. 2026 Aug 03; :JCO2503028. [Online ahead of print]JC
- CONCLUSIONS: Darolutamide demonstrated antitumor activity in AR-positive SGC, with numerically more favorable outcomes with goserelin. Darolutamide plus goserelin may represent a chemotherapy-sparing option in this rare malignancy.
- Publisher Full Text (DOI)
- Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. [Journal Article]J Clin Oncol. 2026 Aug 03; :JCO2502508. [Online ahead of print]JC
- CONCLUSIONS: Overall, these results do not support a change in current adjuvant treatment strategies. mFFX remains the standard adjuvant regimen in PDAC, and the observed lack of benefit in KRAS wild-type tumors should be considered hypothesis-generating and warrants further investigation.
- Publisher Full Text (DOI)